ArticleBMC infectious diseases2025
Time trend prediction of multidrug-resistant/rifampicin-resistant tuberculosis in treatment initiation centers of North East Ethiopia (2015-2023).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) represents a major public health threat and a significant obstacle to global TB control. Analysing trends and forecasting future patterns is critical for effective resource planning. However, the application of predictive modelling for MDR/RR-TB has not been widely explored in Ethiopia.
objectiveThis study aimed to analyse the temporal trends and develop a forecasting model for MDR/RR-TB cases recorded at treatment initiation centres in Northeast Ethiopia between 2015 and 2023.
methodsA retrospective study of all MDR/RR-TB cases diagnosed from January 2015 to December 2023 in Northeast Ethiopia was conducted using data retrieved from six treatment initiation centers (TIC) registries. Data were collected via Kobo Toolbox and analysed with SPSS v27 for descriptive statistics. Seasonal ARIMA models were developed in R to assess trends and generate forecasts, with model selection based on AIC, BIC, and residual diagnostics. Data quality was ensured through verification and consistency checks.
resultsFrom an initial 409 identified individuals, 372 were included in the final analysis after excluding transferred cases. Annual case counts demonstrated instability, with a notable rise between 2017 and 2019 (up to 63.6%) and a distinct decline during 2020-2021, followed by a sharp increase in early 2022. A clear seasonal pattern was observed, with case troughs occurring in August and peaks during the dry season (Bega), followed by a decline in December.
conclusionMDR/RR-TB case trends in Northeast Ethiopia exhibited significant fluctuations over the study period. The pronounced decline in 2020-2021 was likely attributable to service disruptions from the COVID-19 pandemic and regional conflict, while the subsequent surge may reflect a recovery of case detection efforts and the conflict's impact on transmission. TB control programs should prioritize high-risk seasonal periods and ensure resilient systems for timely diagnosis and treatment access amidst external shocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.